SCHEMBL943293

SCHEMBL943293

Cc1cc(C)nc(CN)c1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 12/20 0.50
NOS3 P29474 8/20 0.50
NOS1 P29475 7/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18489365 0.98 NOS2 (0.48) NOS2NOS3NOS1
Hydrochloric Acid SCHEMBL17048489 0.98 NOS2 (0.48) NOS2NOS3NOS1
SCHEMBL521804 0.87 NOS2 (0.48) NOS2NOS3NOS1
SCHEMBL9427715 0.82 NOS2 (0.47) NOS2NOS3NOS1
SCHEMBL15894181 0.80 NOS2 (0.50) NOS2NOS3NOS1
SCHEMBL15259149 0.79 NOS2 (0.69) NOS2NOS3NOS1
SCHEMBL10144472 0.78 NOS2 (0.52) NOS2NOS3NOS1
SCHEMBL7116565 0.78 NOS2 (0.61) NOS2NOS3NOS1
SCHEMBL3713130 0.77 NOTUM (0.38) NOS2NOS3NOS1
SCHEMBL9313998 0.77 NOS2 (0.54) NOS2NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865446-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL KANTO KAGAKU (JP) 2021-09-22 EP claimed
US-9174906-B2 Process for producing optically active secondary alcohol KANTO KAGAKU KABUSHIKI KAISHA (JP) 2015-11-03 US claimed
EP-2865446-A1 Process for producing optically active secondary alcohol Kanto Kagaku Kabushiki Kaisha (JP) 2015-04-29 EP claimed
US-20150031920-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2015-01-29 US claimed
US-11560373-B2 Compounds and their use as PDE4 activators MIRONID LIMITED (GB) 2023-01-24 US disclosed
US-20230017272-A1 NEW WATER SOLUBLE MONO-BRANCHED AND DI-BRANCHED COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES CISBIO BIOASSA YS (FR) 2023-01-19 US disclosed
EP-3774780-B1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LTD (GB) 2022-11-23 EP disclosed
EP-2865446-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL KANTO KAGAKU (JP) 2021-09-22 EP disclosed
EP-3334721-B1 CGRP RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2021-04-28 EP disclosed
EP-3341370-B1 CGRP RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2021-04-28 EP disclosed
EP-3774780-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2021-02-17 EP disclosed
US-20210032231-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2021-02-04 US disclosed
US-20110009390-A1 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS F2G LIMITED (GB) 2011-01-13 US disclosed
EP-2173749-B1 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS F2G LTD (GB) 2011-01-12 EP disclosed
EP-2173749-A1 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS F2G Limited (GB) 2010-04-14 EP disclosed
WO-2009130481-A1 PYRROLE ANTIFUNGAL AGENTS F2G LTD (GB) 2009-10-29 WO disclosed
WO-2008145963-A1 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS F2G LIMITED (GB) 2008-12-04 WO disclosed
US-5290797-A Benzopyran compounds ADIR ET COMPAGNIE (FR) 1994-03-01 US disclosed
US-4869983-A SENSITIZERS, CHARGE GENERATING COMPOUNDS HOECHST AKTIENGESELLSCHAFT (DE) 1989-09-26 US disclosed
US-4820718-A PLATELET ACTIVATING FACTOR INHIBITORS SANDOZ PHARM. CORP. (US) 1989-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032231-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE4C NOS2 501/4885NOS3 347/4885NOS1 527/4885
US-20150031920-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL ADH1A, ADH1C, ADH5 NOS2 2953/4885NOS3 2532/4885NOS1 2633/4885
US-20230017272-A1 NEW WATER SOLUBLE MONO-BRANCHED AND DI-BRANCHED COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES LASP1, RCC1, AQP1 NOS2 2332/4885NOS3 1824/4885NOS1 2141/4885
US-20110009390-A1 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS NAT1, FOXM1, CYP51A1 NOS2 56/4885NOS3 106/4885NOS1 68/4885
US-11560373-B2 Compounds and their use as PDE4 activators PDE4A, PDE4B, PDE4C NOS2 501/4885NOS3 347/4885NOS1 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.